Almawave and the EU-funded VαMPiRE project: the value of AI in clinical research

Parkinson’s disease (PD) is one of the most complex challenges in modern medicine. Today, it affects more than 9.4 million people worldwide.

Disability and mortality linked to Parkinson’s are rising faster than for any other neurological condition. Yet despite decades of research, the mechanisms behind the onset and progression of the disease are still not fully understood.

That is why early diagnosis—and identifying effective treatments—has become an urgent priority.

This need is the starting point for VαMPiRE (Validation of α-synuclein Modifications in Parkinson’s dIsoRder Evolution), a European Union–funded initiative aimed at developing an in vitro diagnostic (IVD) test capable of detecting the earliest stages of the disease and estimating prognosis and progression. It’s an innovative approach that combines advanced biological analysis with artificial intelligence models.

The goal is to enable, from 2028 onwards, the early diagnosis of around 270,000 new Parkinson’s cases each year.

The project—currently underway—is being delivered by a broad consortium of companies, organizations, universities, and international institutes, including Almawave. Almawave is responsible for carrying out AI-based algorithmic studies to analyze test results and generate insights into both familial patterns and the predictive power of biomarkers for disease evolution.

VαMPiRE sits within Horizon Europe, the European Commission’s flagship program for boosting competitiveness and fostering innovation across EU Member States.

With a budget of €95 billion, Horizon Europe supports concrete solutions across many domains—from ocean protection to addressing the climate crisis.

Among its most ambitious priorities are health-related challenges, including Parkinson’s research. VαMPiRE aims to transform early diagnosis, prognosis, and disease management through cutting-edge science and innovation.

Advances in Parkinson’s pathophysiology suggest promising treatments to slow progression, but reversing cellular degeneration remains out of reach for now. At the same time, the lack of validated biomarkers makes it difficult to identify Parkinson’s in its early stages.

Recent studies show that the accumulation of misfolded α-synuclein (α-Syn) proteins is a hallmark of Parkinson’s. The detection of α-Syn in neuron-derived extracellular vesicles (NDEVs) in patients also points to the potential for new diagnostic methods.

This is where VαMPiRE takes shape: the project aims to run a longitudinal study on a large, controlled cohort—600 participants with Parkinson’s and 600 without—to investigate α-Syn isoforms and related biomarkers in NDEVs, supporting the development of an In Vitro Diagnostic (IVD) test.

The protocol includes collecting two blood samples from participants with Parkinson’s over a 24-month period, and a single baseline sample from control participants without Parkinson’s.

All participants will be monitored regularly for 24 months, alongside disease progression and treatments. Control participants who develop Parkinson’s will be included in a third cohort (estimated at around 24 individuals, based on a 4% incidence rate) to confirm the test’s sensitivity in asymptomatic subjects.

The program aims to identify the 4% of initially non-Parkinson’s participants who go on to develop the disease—demonstrating the value of biomarkers for early diagnosis.

Finally, the prototype will undergo rigorous validation by comparing detection performance at baseline and after 24 months, to predict disease evolution and treatment response.

VαMPiRE’s approach includes the use of AI models to analyze biomarker data and turn complex information into evidence that can support clinical research. This makes it possible to run analyses that are accurate, reproducible, and scalable—key requirements for developing an IVD diagnostic test.

This is where Almawave’s contribution comes in. The company has been entrusted with the critical task of developing and applying AI-driven algorithmic analyses to interpret test results and generate insights that assess both whether there are patterns suggestive of familial links, and the predictive ability of biomarkers in relation to disease progression.

Almawave has already completed an initial phase of work, conducting a retrospective study on approximately 200 patients to help develop statistical tools capable of extracting meaningful signals from real-world data on people living with Parkinson’s disease.

The potential benefits of VαMPiRE span the entire Parkinson’s care pathway—from early screening to personalised disease management and even supporting the development of new therapeutic strategies.

The ambition is to create value not only for clinical research, but also for patients and healthcare systems.

According to the project’s estimates and objectives, by 2028 VαMPiRE could:

• Enable the early diagnosis of around 270,000 new Parkinson’s cases each year, detecting the disease at a stage when interventions can be more effective
• Help improve disease management for over 9.4 million people currently living with Parkinson’s globally
• Significantly reduce the disability burden associated with the disease, preventing the loss of approximately 5.8 million disability-adjusted life years (DALYs)
• Lay the scientific and technological foundations for developing and implementing more targeted, personalised treatments.

VαMPiRE is a concrete example of how European research, technological innovation, and artificial intelligence can converge to tackle one of the most complex health challenges of our time—opening new possibilities for predictive and preventive medicine.

Discover how Almawave solutions are driving innovation in healthcare.